When Initial Combination Antibiotic Therapy Fails in Severe Bacillary Angiomatosis with Multifocal Bartonella Infection or Clinical Decompensation
Clinical Scenario
This protocol addresses patients with severe bacillary angiomatosis — specifically those presenting with multifocal Bartonella infection or evidence of clinical decompensation — in whom initial antibiotic combination therapy has not achieved the expected serological response.
Previous Treatment Line: Goals Not Achieved
Initial management with combination therapy (doxycycline or erythromycin plus rifampin) failed to reach its defined endpoint: at least a fourfold decrease in anti-Bartonella IFA IgG antibody titers, assessed on sequential endpoint titers every 6 to 8 weeks during treatment. Non-achievement of this serological milestone triggers escalation to this next-line protocol.
Next-Line Approach (Partial Summary)
Management calls for switching to a different preferred antibiotic regimen while continuing a rifamycin class antibiotic as part of combination therapy.
Full agent selection, sequencing, and duration are detailed in the complete structured protocol — accessible below.
References
- For severe Bartonella infections (i.e., patients with multifocal disease or evidence of clinical decompensation), combination therapy using erythromycin or doxycycline with a rifamycin class antibiotic is recommended (BIII); intravenous therapy may be needed initially (AIII).
- Among patients who fail to respond to initial treatment, switching to a different preferred regimen (for example, from doxycycline to erythromycin) may be considered, again with treatment duration of ≥3 months (AIII).
- For severe infections, the addition of a rifamycin class antibiotic is indicated (AIII).
View source ↗